Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

abstract：:MicroRNAs (miRNAs) are aiding our understanding of cancer biology, and are now coming close to therapeutic use as well. Here, we focus specifically on the interaction between miRNAs and genomic instability. MiRNA regulation is essential to many cellular processes, and escape from this regulatory network seems to be a ...

journal_title：Seminars in oncology

authors： Landau DA,Slack FJ

更新日期：2011-12-01 00:00:00

abstract：:Many small cell carcinomas share morphological and physiological characteristics with normal and neoplastic cells of Pearse's APUD series, including pulmonary APUD cells and pulmonary carcinoid tumors. There is very likely more than one type of APUD cell in the lung, and conclusions that small cell carcinomas and carc...

journal_title：Seminars in oncology

authors： Tischler AS

更新日期：1978-09-01 00:00:00

abstract：:The EORTC Lung Cancer Working Party investigated the effects of combination therapy with VP-16 (Ve-Pesid) and cisplatin in the treatment of non-small-cell lung cancer (NSCLC). Neither agent alone is recognized as being associated with a high rate of response in NSCLC, but the combination proved beneficial in our hands...

journal_title：Seminars in oncology

authors： Klastersky J

更新日期：1985-03-01 00:00:00

abstract：:At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity--testicular cancer and smal...

journal_title：Seminars in oncology

authors： Loehrer PJ,Williams SD,Nichols CR,Einhorn LH

更新日期：1992-02-01 00:00:00

abstract：:Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's...

journal_title：Seminars in oncology

authors： Hricak H,Schöder H,Pucar D,Lis E,Eberhardt SC,Onyebuchi CN,Scher HI

更新日期：2003-10-01 00:00:00

abstract：:Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer. Criteria for an effective combination include use of drugs with different mechanisms of action, nonoverlapping toxic effects, and synergistic, or at least additive, antitumor activity. Paclitaxel (Taxol; B...

journal_title：Seminars in oncology

authors： Holmes FA

更新日期：1996-10-01 00:00:00

abstract：:Complementary and alternative therapies are used with increasing frequency in men with prostate cancer. However, little is known about the efficacy of such therapies for this cancer. While epidemiological data support the association between intake of certain micronutrients with development of prostate cancer, there e...

journal_title：Seminars in oncology

authors： Oh WK,Small EJ

更新日期：2002-12-01 00:00:00

abstract：:Intraoperative lymphatic mapping and selective lymphadenectomy for solid malignancies is a novel technique, having been introduced into surgical practice in the last 12 years. Dissemination of this technique among surgeons has followed a course similar to that found with the introduction of new laparoscopic techniques...

journal_title：Seminars in oncology

authors： Wilke LG

更新日期：2004-06-01 00:00:00

abstract：:Recent data indicate that cellular immune responses can produce an anticancer effect. Two types of cellular immune responses appear to be clinically relevant: antigen specific immunity mediated by T cells that recognize tumor-associated peptide antigen expressed on surface HLA class I or class II molecules, and antige...

journal_title：Seminars in oncology

authors： Waller EK

更新日期：2004-04-01 00:00:00

abstract：:Adjuvant chemotherapy in breast cancer has clearly been shown to reduce mortality. The benefits extend to pre- and postmenopausal women and those with node-negative, node-positive, estrogen receptor (ER)-positive, and ER-negative disease. Updated data regarding chemoendocrine therapy in postmenopausal women and anthra...

journal_title：Seminars in oncology

authors： Tan AR,Swain SM

更新日期：2001-08-01 00:00:00

abstract：:Many novel antifolate compounds with unique pharmacologic properties are currently in clinical development. These newer antifolates differ from methotrexate, the most widely used and studied drug in this class, in terms of their lipid solubility and cellular transport affinity, their level of polyglutamation, and thei...

journal_title：Seminars in oncology

authors： Takimoto CH

更新日期：1997-10-01 00:00:00

abstract：:Platinum compounds have long played a role in the treatment of gynecologic cancers. Single-agent cisplatin and carboplatin have shown activity in endometrial cancer, and more recent studies have begun to investigate a variety of new platinum-based combinations. In cervical cancer, chemotherapy is used primarily to tre...

journal_title：Seminars in oncology

authors： Muggia FM

更新日期：2004-12-01 00:00:00

abstract：:Constitutive expression of interferons (IFNs) and activation of their signaling pathways have pivotal roles in host responses to malignant cells in the tumor microenvironment. IFNs are induced by the innate immune system and in tumors through stimulation of Toll-like receptors (TLRs) and through other signaling pathwa...

journal_title：Seminars in oncology

authors： Cheon H,Borden EC,Stark GR

更新日期：2014-04-01 00:00:00

abstract：:Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not c...

journal_title：Seminars in oncology

authors： Vose JM,Bierman PJ,Armitage JO

更新日期：1990-12-01 00:00:00

abstract：:Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that overexpress the IL-2 receptor. The human IL-2 receptor exists in three isoforms: low (CD25), intermediate (CD122/CD132), and high (CD25/CD122/CD132) affinity. The high-a...

journal_title：Seminars in oncology

authors： Foss F

更新日期：2006-02-01 00:00:00

abstract：:In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

journal_title：Seminars in oncology

authors： Chmura SJ,Milano MT,Haraf DJ

更新日期：2004-12-01 00:00:00

abstract：:Blast crisis terminates the life of the majority (approximately 80%) of patients with CML. The time of its onset appears to be a random phenomenon, varying from a probable coincidence occurrence with the onset of CML to more than a decade after onset of the chronic phase. In most patients the diagnosis is obvious as v...

journal_title：Seminars in oncology

authors： Boggs DR

更新日期：1976-09-01 00:00:00

abstract：:Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or variable to fulfill this role. Our experience suggests that variable reag...

journal_title：Seminars in oncology

authors： Ferry-Galow KV,Makhlouf HR,Wilsker DF,Lawrence SM,Pfister TD,Marrero AM,Bigelow KM,Yutzy WH,Ji JJ,Butcher DO,Gouker BA,Kummar S,Chen AP,Kinders RJ,Parchment RE,Doroshow JH

更新日期：2016-08-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent w...

journal_title：Seminars in oncology

authors： Manegold C

更新日期：1998-08-01 00:00:00

abstract：:Previously untreated patients with stages I to IV, N0-3, M0 unresectable non-small cell lung cancer were randomized to arm I (conventional radiotherapy [RT], 60 Gy in 30 fractions over 6 weeks), arm II (accelerated RT, 60 Gy in 30 fractions over 3 weeks), arm III (conventional RT, as in arm I, plus carboplatin 70 mg/m...

journal_title：Seminars in oncology

authors： Bishop JF,Ball D,Crennan E,Ryan G,Davis S,Toner G,O'Brien P,Olver I

更新日期：1994-06-01 00:00:00

abstract：:This phase I trial was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin (400 mg/m2) as first-line chemotherapy for stage IIIC/IV ovarian adenocarcinoma. After premedication, paclitaxel was infu...

journal_title：Seminars in oncology

authors： Lhommé C,Kerbrat P,Lejeune C,Guastalla JP,Fumoleau P,Goupil A,Héron JF,Cassin MA,Pruvot I,Soares JA,Chazard M

更新日期：1996-10-01 00:00:00

abstract：:In the last decade our understanding of chronic lymphocytic leukemia (CLL) biology and pathogenesis has increased substantially. These insights have led to the development of several new agents with novel mechanisms of action prompting a change in therapeutic approaches from chemotherapy-based treatments to targeted t...

journal_title：Seminars in oncology

authors： Herman SE,Wiestner A

更新日期：2016-04-01 00:00:00

abstract：:The purpose of this pilot study was to determine the safety and feasibility of accelerated fractionation (via concomitant boost) radiotherapy (XRT) with concurrent carboplatin/paclitaxel chemotherapy for locally advanced stage III non-small cell lung carcinoma. Radiotherapy consisted of 3-dimensional conformal techniq...

journal_title：Seminars in oncology

authors： Machtay M,Washam C,Devine P

更新日期：2005-04-01 00:00:00

abstract：:First-line therapy for men with metastatic or recurrent prostate cancer following definitive local therapy is medical or surgical castration. Though effective initially in most patients, the majority of tumors develop castration resistance, necessitating the addition of further therapy. The historic treatment paradigm...

journal_title：Seminars in oncology

authors： Hoffman-Censits J,Fu M

更新日期：2013-06-01 00:00:00

abstract：:Pathologic complete response after neoadjuvant chemoradiation therapy is associated with increased survival in esophageal cancer. Early detection of response or nonresponse to neoadjuvant chemoradiation might allow individualization of treatment strategies and avoidance of unnecessary treatment. Positron emission tomo...

journal_title：Seminars in oncology

authors： Chao KS

更新日期：2006-12-01 00:00:00

abstract：:The current resurgence in the use of nomograms as diagnostic and prognostic tools has legitimate roots in their effectiveness in facilitating communication between the doctor and patient. By returning to a more classical approach to nomography, graphical insights can further enlighten the patient beyond what can be ac...

journal_title：Seminars in oncology

authors： Kattan MW,Marasco J

更新日期：2010-02-01 00:00:00

abstract：:Inhibition of cellular DNA synthesis is the major action of gemcitabine. In cells, this drug is converted to its triphosphate (dFdCTP), which is incorporated into DNA and terminates DNA strand elongation. After incorporation of gemcitabine nucleotide into the DNA strand, one more deoxynucleotide is incorporated, and t...

journal_title：Seminars in oncology

authors： Huang P,Plunkett W

更新日期：1995-08-01 00:00:00

abstract：:Chemotherapy for prostate cancer currently has an established role in the treatment of hormone-refractory prostate cancer. There is strong evidence that combined modality treatment with androgen ablation in addition to radiotherapy provides a benefit above and beyond radiotherapy alone in patients with a poor prognosi...

journal_title：Seminars in oncology

authors： Sandler HM,Narayan S,Smith DC

更新日期：2003-08-01 00:00:00

abstract：:Solid malignancies often exhibit high interstitial fluid pressure (IFP), which causes poor uptake of anticancer drugs. While there are several mechanisms that regulate IFP in tumors, activation of platelet-derived growth factor receptor, which is expressed in various cell types within the tumor microenvironment, has b...

journal_title：Seminars in oncology

authors： Pietras K

更新日期：2004-04-01 00:00:00

abstract：:Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck. Excluding cases that are considered to arise from skin, SCC in the head and neck has been found to develop in nearly all structures associated wit...

journal_title：Seminars in oncology

authors： Renner G

更新日期：2007-02-01 00:00:00